Combined Company to Deliver Comprehensive, Integrated Solutions for Life Science Organizations Worldwide BOSTON , Sept. 18, 2024 /PRNewswire/ -- Riverside Partners, LLC (" Riverside "), a Boston -based private equity firm, today announced the strategic combination of Sequoia Biotech Consulting ("Sequoia"), a leading life sciences service provider helping organizations to scale rapidly and to deliver high-quality therapeutics, and Syner-G BioPharma Group ("Syner-G"), a leading provider of integrated regulatory and biopharmaceutical development services. The combined company will offer comprehensive, integrated solutions to clients across the global pharmaceutical, biotechnology, and medical device sectors.
Riverside invested in Syner-G and Sequoia in October 2020 and December 2021 , respectively. The strategic combination of Sequoia and Syner-G is the culmination of years of investment and business transformation by Riverside to create a market leading organization with approximately 500 employees, combining expertise in process and analytical development, regulatory strategy, submissions support, quality and compliance, operational excellence, program management, and engineering and facilities services. By integrating these capabilities, the newly formed entity offers comprehensive, end-to-end solutions across the development and manufacturing continuum, empowering life sciences companies to accelerate the delivery of innovative therapies and technologies.
"We are thrilled to.